-
Je něco špatně v tomto záznamu ?
Child outcomes after prenatal exposure to platinum and taxane-based chemotherapy: an unplanned interim analysis of the international network on cancer, infertility, and pregnancy study
IA. Van Assche, K. Van Calsteren, EA. Huis In 't Veld, M. van Gerwen, L. Heylen, CL. LeJeune, E. Cardonick, MJ. Halaska, R. Fruscio, M. Fumagalli, EM. van Dijk-Lokkart, J. Lemiere, M. van Grotel, L. Lagae, MM. van den Heuvel-Eibrink, F. Amant
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2018
PubMed Central
od 2018
Europe PubMed Central
od 2018
ROAD: Directory of Open Access Scholarly Resources
od 2018
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Platina and taxanes are frequently used chemotherapeutic agents to treat cancer, also when diagnosed during pregnancy. This report presents an interim analysis of the largest series of children prenatally exposed to platinum and/or taxane agents and aims to determine their physical health and neurocognitive outcomes. METHODS: As part of a multicentre, prospective cohort study (ClinicalTrials.gov: NCT00330447), children born between 2000 and 2022 were assessed between 2005 and 2024 at ages 1.5-18 years (interim analysis; median length of follow-up, 3.2 years (IQR 3.0-6.4)) by a comprehensive neurocognitive test battery, parent-reported questionnaires, and a physical assessment. Mixed-effects regression and Type III Analysis of Variance models were used to investigate associations between these outcomes and platinum/taxane cumulative dose and agent type, with best-fit models corrected for age and covariates (gestational age at birth, chemotherapy timing, other chemotherapy, sex, parental education level, maternal death). FINDINGS: In total, 144 children were included (13% exposed to platinum, 62% to taxanes, 25% to both). Of these, 101 were assessed at age 1.5 years, 96 at age 3, 63 at age 6, 32 at age 9, 18 at age 12, 7 at age 15, and 2 at age 18 years. Neurocognitive outcomes were within normal ranges across all ages, compared with test-specific normative data. Eight children (6%) reported ototoxicity, seven (5%) reported chronic medical conditions, three (2%) had congenital malformations, and two (1%) were diagnosed with Attention-Deficit Hyperactivity Disorder. Thirty-three children (23%) needed extra neurocognitive support, of which 64% were born preterm. Children prenatally exposed to paclitaxel scored lower on visuospatial (β = 0.64 ± 0.21, p = 0.0052) and verbal memory (β = 0.68 ± 0.27, p = 0.015) than those exposed to docetaxel. INTERPRETATION: In this interim analysis, we found normal neurocognitive outcomes and no increase in congenital malformations nor medical conditions after prenatal exposure to platinum/taxane-based chemotherapy. However, owed to the limited number of older children, further investigation regarding their potential neurotoxicity and its long term effects is necessary in follow-up studies with larger samples. FUNDING: Kom Op Tegen Kanker, KWF Kankerbestrijding, Stichting Tegen Kanker, Cooperatio program, Research Foundation Flanders.
Amsterdam Reproduction and Development Child Development Amsterdam the Netherlands
Center for Gynecological Oncology Netherlands Cancer Institute Amsterdam Netherlands
Department of Clinical Sciences and Community Health University of Milan Milano Italy
Department of Development and Regeneration Unit of Woman and Child KU Leuven Belgium
Department of Obstetrics and Gynaecology Unit of Foetomaternal Medicine UZ Leuven Belgium
Department of Obstetrics and Gynecology Cooper University Health Care Camden NJ USA
Department of Oncology Unit of Gynaecological Oncology KU Leuven Belgium
Department of Oncology Unit of Pediatric Oncology KU Leuven Belgium
Department of Pediatrics Unit of Pediatric Hemato Oncology UZ Leuven Belgium
Department of Pediatrics Unit of Pediatric Neurology UZ Leuven Belgium
Division of Gynaecological Oncology Department of Obstetrics and Gynaecology UZ Leuven Belgium
Faculty of Psychology and Educational Sciences Unit of Clinical Psychology KU Leuven Belgium
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico NICU Milano Italy
Princess Máxima Center for Pediatric Oncology Utrecht Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002031
- 003
- CZ-PrNML
- 005
- 20250123101947.0
- 007
- ta
- 008
- 250117e20241111enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eclinm.2024.102922 $2 doi
- 035 __
- $a (PubMed)39588212
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Van Assche, Indra A $u Department of Development and Regeneration, Unit of Woman and Child, KU Leuven, Belgium
- 245 10
- $a Child outcomes after prenatal exposure to platinum and taxane-based chemotherapy: an unplanned interim analysis of the international network on cancer, infertility, and pregnancy study / $c IA. Van Assche, K. Van Calsteren, EA. Huis In 't Veld, M. van Gerwen, L. Heylen, CL. LeJeune, E. Cardonick, MJ. Halaska, R. Fruscio, M. Fumagalli, EM. van Dijk-Lokkart, J. Lemiere, M. van Grotel, L. Lagae, MM. van den Heuvel-Eibrink, F. Amant
- 520 9_
- $a BACKGROUND: Platina and taxanes are frequently used chemotherapeutic agents to treat cancer, also when diagnosed during pregnancy. This report presents an interim analysis of the largest series of children prenatally exposed to platinum and/or taxane agents and aims to determine their physical health and neurocognitive outcomes. METHODS: As part of a multicentre, prospective cohort study (ClinicalTrials.gov: NCT00330447), children born between 2000 and 2022 were assessed between 2005 and 2024 at ages 1.5-18 years (interim analysis; median length of follow-up, 3.2 years (IQR 3.0-6.4)) by a comprehensive neurocognitive test battery, parent-reported questionnaires, and a physical assessment. Mixed-effects regression and Type III Analysis of Variance models were used to investigate associations between these outcomes and platinum/taxane cumulative dose and agent type, with best-fit models corrected for age and covariates (gestational age at birth, chemotherapy timing, other chemotherapy, sex, parental education level, maternal death). FINDINGS: In total, 144 children were included (13% exposed to platinum, 62% to taxanes, 25% to both). Of these, 101 were assessed at age 1.5 years, 96 at age 3, 63 at age 6, 32 at age 9, 18 at age 12, 7 at age 15, and 2 at age 18 years. Neurocognitive outcomes were within normal ranges across all ages, compared with test-specific normative data. Eight children (6%) reported ototoxicity, seven (5%) reported chronic medical conditions, three (2%) had congenital malformations, and two (1%) were diagnosed with Attention-Deficit Hyperactivity Disorder. Thirty-three children (23%) needed extra neurocognitive support, of which 64% were born preterm. Children prenatally exposed to paclitaxel scored lower on visuospatial (β = 0.64 ± 0.21, p = 0.0052) and verbal memory (β = 0.68 ± 0.27, p = 0.015) than those exposed to docetaxel. INTERPRETATION: In this interim analysis, we found normal neurocognitive outcomes and no increase in congenital malformations nor medical conditions after prenatal exposure to platinum/taxane-based chemotherapy. However, owed to the limited number of older children, further investigation regarding their potential neurotoxicity and its long term effects is necessary in follow-up studies with larger samples. FUNDING: Kom Op Tegen Kanker, KWF Kankerbestrijding, Stichting Tegen Kanker, Cooperatio program, Research Foundation Flanders.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Van Calsteren, Kristel $u Department of Development and Regeneration, Unit of Woman and Child, KU Leuven, Belgium $u Department of Obstetrics and Gynaecology, Unit of Foetomaternal Medicine, UZ Leuven, Belgium
- 700 1_
- $a Huis In 't Veld, Evangeline A $u Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands $u Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
- 700 1_
- $a van Gerwen, Mathilde $u Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands $u Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands $u Department of Child & Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, University of Amsterdam, the Netherlands
- 700 1_
- $a Heylen, Laura $u Faculty of Psychology and Educational Sciences, Unit of Clinical Psychology, KU Leuven, Belgium
- 700 1_
- $a LeJeune, Charlotte L $u Department of Obstetrics and Gynaecology, Unit of Foetomaternal Medicine, UZ Leuven, Belgium $u Department of Oncology, Unit of Gynaecological Oncology, KU Leuven, Belgium
- 700 1_
- $a Cardonick, Elyce $u Department of Obstetrics and Gynecology, Cooper University Health Care, Camden, NJ, USA
- 700 1_
- $a Halaska, Michael J $u Department of Obstetric Gynecology, University Hospital Kralovske Vinohrady and 3rd Medical Faculty, Charles University, Prague, Czechia
- 700 1_
- $a Fruscio, Robert $u Department of Medicine and Surgery, Clinic of Obstetrics and Gynecology, University of Milan-Bicocca, Fondazione IRCCS San Gerardo, Monza, Italy
- 700 1_
- $a Fumagalli, Monica $u Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy $u Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, NICU, Milano, Italy
- 700 1_
- $a van Dijk-Lokkart, Elisabeth M $u Department of Child & Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, University of Amsterdam, the Netherlands $u Amsterdam Reproduction and Development, Child Development, Amsterdam, the Netherlands
- 700 1_
- $a Lemiere, Jurgen $u Department of Oncology, Unit of Pediatric Oncology, KU Leuven, Belgium $u Department of Pediatrics, Unit of Pediatric Hemato-Oncology, UZ Leuven, Belgium
- 700 1_
- $a van Grotel, Martine $u Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
- 700 1_
- $a Lagae, Lieven $u Department of Development and Regeneration, Unit of Woman and Child, KU Leuven, Belgium $u Department of Pediatrics, Unit of Pediatric Neurology, UZ Leuven, Belgium
- 700 1_
- $a van den Heuvel-Eibrink, Marry M $u Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands $u University Medical Center Utrecht-Wilhelmina Children's Hospital, Division of Child Health, Utrecht, Netherlands
- 700 1_
- $a Amant, Frédéric $u Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands $u Department of Oncology, Unit of Gynaecological Oncology, KU Leuven, Belgium $u Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, UZ Leuven, Belgium
- 773 0_
- $w MED00200566 $t EClinicalMedicine $x 2589-5370 $g Roč. 78 (20241111), s. 102922
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39588212 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250117 $b ABA008
- 991 __
- $a 20250123101941 $b ABA008
- 999 __
- $a ok $b bmc $g 2254450 $s 1238034
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 78 $c - $d 102922 $e 20241111 $i 2589-5370 $m EClinicalMedicine $n EClinicalMedicine $x MED00200566
- LZP __
- $a Pubmed-20250117
